7.3 Pharmacokinetics and Pharmacodynamics in Product Development

Introduction to Pharmacology in Clinical Trials

Understanding how an investigational drug interacts with the human body is the primary goal of early-phase clinical research. This interaction is divided into two major disciplines: Pharmacokinetics (PK) and Pharmacodynamics (PD). A simple way to remember the distinction is:

• Pharmacokinetics (PK): What the body does to the drug.
• Pharmacodynamics (PD): What the drug does to the body.

For a Clinical Research Coordinator (CCRC), especially one working in Phase I or Phase II trials, executing protocols designed to measure PK and PD parameters requires extreme precision. Missed blood draws or improper sample processing can render a subject's data entirely useless, costing the sponsor thousands of dollars and potentially requiring additional subjects to be exposed to the investigational product.

---

Pharmacokinetics (PK): The ADME Process

Pharmacokinetics tracks the journey of a drug through the body. This journey is characterized by four distinct phases, collectively known by the acronym ADME.

Absorption

Absorption is the process by which a drug moves from its site of administration into the systemic circulation (bloodstream). The route of administration heavily influences absorption.

• Intravenous (IV) Administration: The drug is injected directly into the bloodstream, resulting in 100% absorption instantaneously.
• Oral Administration: The drug must pass through the gastrointestinal tract and survive the "first-pass effect" (metabolism in the liver) before reaching systemic circulation.

Bioavailability is a key PK concept related to absorption; it is the fraction of an administered dose of unchanged drug that reaches the systemic circulation.

Distribution

Once in the bloodstream, the drug is distributed throughout the body's tissues and organs. Distribution depends on blood flow, tissue permeability, and the extent to which the drug binds to plasma proteins (like albumin). A drug that is highly bound to plasma proteins remains trapped in the blood, while only the "free" (unbound) fraction of the drug can exit the bloodstream to exert a therapeutic effect at the target tissue.

Metabolism (Biotransformation)

Metabolism is the process by which the body chemically alters the drug, usually to make it easier to excrete. The liver is the primary organ for drug metabolism, utilizing the cytochrome P450 (CYP450) enzyme system.

Understanding metabolism is crucial for identifying potential drug-drug interactions. If two drugs are metabolized by the same CYP450 enzyme, they may compete, leading to elevated, potentially toxic levels of one drug in the body.

Excretion

Excretion is the removal of the drug and its metabolites from the body. The kidneys are the primary organs of excretion, eliminating drugs through urine. Other routes include feces, bile, sweat, and exhaled air. Renal impairment can severely affect a drug's clearance, often requiring dose adjustments.

Half-Life (t½)

The half-life of a drug is the time it takes for the concentration of the drug in the blood plasma to decrease by 50%. It generally takes about five half-lives for a drug to be almost completely eliminated from the body. Half-life is critical for determining dosing intervals; a drug with a short half-life may need to be taken three times a day, while a drug with a long half-life might be taken once daily.

---

Pharmacodynamics (PD)

While PK maps the concentration of a drug over time, Pharmacodynamics (PD) examines the drug's biological and physiological effects. PD studies the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects.

Key PD concepts include:

• Mechanism of Action: How the drug works at the cellular or molecular level (e.g., blocking a specific receptor, inhibiting an enzyme).
• Agonists vs. Antagonists: An agonist binds to a receptor and activates it, producing a biological response. An antagonist binds to a receptor but blocks it, preventing a response.
• Dose-Response Relationship: The correlation between the dose of the drug administered and the magnitude of the effect produced. Clinical trials seek to identify the optimal dose that maximizes efficacy while minimizing toxicity.

---

The CCRC's Role in PK/PD Studies

Trials with heavy PK and PD components, especially Phase I Single Ascending Dose (SAD) or Multiple Ascending Dose (MAD) studies, are incredibly demanding for the clinical site.

Time-Critical Interventions

PK profiles are generated by mapping drug concentration in the blood over a very specific timeline. A typical PK day might involve blood draws at 0 (pre-dose), 15 mins, 30 mins, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-dose.

• Absolute Precision: If the protocol mandates a 15-minute post-dose PK draw, drawing the blood at 20 minutes is a protocol deviation. The exact time of the blood draw must be meticulously documented.
• Coordinated Effort: CCRCs must often coordinate with nursing staff, phlebotomists, and the investigational pharmacy to ensure the drug is administered exactly on time and samples are drawn at the precise intervals.

Sample Processing and Shipping

PK samples are highly sensitive. Once blood is drawn, it usually must be immediately inverted, placed on ice, centrifuged within a specific timeframe, aliquoted into separate vials, and frozen at -20°C or -80°C.

• Cold Chain Logistics: The CCRC ensures that the "cold chain" is maintained. If a sample that requires -80°C storage sits on a counter at room temperature for an hour, the drug compounds in the blood may degrade, invalidating the sample.
• Meticulous Labeling: Accurate labeling of PK aliquots is non-negotiable. A mislabeled tube means the sponsor cannot correlate the drug concentration to the correct time point or subject.

By executing PK and PD protocols flawlessly, the CCRC provides the sponsor with the clean, reliable data necessary to determine safe dosing regimens for future, larger-scale clinical trials.